Latest Intermune Inc (ITMN) Headlines InterMune
Post# of 5
InterMune Announces Proposed Public Offering of Common Stock
PR Newswire - Wed Mar 12, 3:02PM CDT
InterMune, Inc. (NASDAQ: ITMN) today announced that it plans to offer, subject to market and other conditions, 7,500,000 shares of its common stock in an underwritten public offering. The company expects to grant the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock in connection with the offering. All of the shares in the offering will be sold by InterMune. The shares will be issued pursuant to a prospectus supplement filed as part of a shelf registration statement previously filed with the Securities and Exchange Commission (SEC) on Form S-3.
Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 12, 9:50AM CDT
Last week's highlights include safety concerns regarding a new class of drugs and takeover rumors.
Insider Trading Alert - ITMN, M And ILMN Traded By Insiders
at The Street - Wed Mar 12, 9:45AM CDT
Stocks with insider trader activity include ITMN, M and ILMN
, Terra Tech OTCQB TRTC Share price Grows Green up 16%
M2 - Wed Mar 12, 9:23AM CDT
March 12, 2014 Vancouver (321gostocks) -- Biotech news and Marijuana's continued rise in growing demand results in companies taking steps to advantage of strategic alliances: OSL Holdings, Inc. (OTC: OSLH), Terra Tech Corp. (OTC: TRTC), Growlife, Inc. (OTCBB: PHOT), Medical Marijuana, Inc. (OTC: MJNA) and InterMune, Inc. (NASDAQ: ITMN).
Why InterMune, Inc. Shares Rallied This Morning
Brian Pacampara, The Motley Fool - Motley Fool - Tue Mar 11, 9:26AM CDT
While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a look at particularly stock-shaking analyst upgrades and downgrades -- just in case their reasoning behind the call makes sense. ...
InterMune Rises on Takeover Rumor - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 4:00PM CDT
Shares of InterMune were up around 10.8% on Mar 7 to end the day's trading at $33.87
Top Gainers under the Lens: Advanced Micro Devices, Big Lots, InterMune, and Palo Alto Networks
PR Newswire - Mon Mar 10, 12:38PM CDT
The US markets saw a mixed sentiment on Friday, March 07, 2014, with the NASDAQ Composite closing at 4,336.22, down 0.37%, the Dow Jones Industrial Average ending the session at 16,452.72, up 0.19% and the S&P 500 edging 0.05% higher to finish the trading session at 1,878.04. During the session, gains in the Financials, Energy and Industrials sectors positively impacted the broader market, while some retraction came in from Health Care, Materials and Information Technology sectors. A number of stocks saw large movements, including Advanced Micro Devices Inc. (NYSE: AMD), Big Lots Inc. (NYSE: BIG), InterMune Inc. (NASDAQ: ITMN), and Palo Alto Networks Inc. (NYSE: PANW), which were amongst the top gainers for the session. Free research on these four companies can be accessed at:
Cannabis & Biotech Advancers Forging Ahead - Company Contracts With One of The Oldest Marijuana Dispensaries in California
PR Newswire - Mon Mar 10, 8:05AM CDT
Biotech news and Marijuana's continued rise in growing demand results in companies taking steps to advantage of strategic alliances: OSL Holdings, Inc. (OTC: OSLH), Terra Tech Corp. (OTC: TRTC), Growlife, Inc. (OTCBB: PHOT), Medical Marijuana, Inc. (OTC: MJNA) and InterMune, Inc. (NASDAQ: ITMN).
3 Biotech Stocks Spiking on Big Volume
at The Street - Mon Mar 10, 5:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
InterMune Wins Amid More Takeover Rumors
David Williamson, The Motley Fool - Motley Fool - Fri Mar 07, 6:54PM CST
InterMune was the big winner in biotech today, up around 10% on rumors of a buyout. However, in this video from Friday's Market Checkup , Motley Fool health-care analyst David Williamson says that these rumors are as of yet completely...
Nasdaq stocks posting largest percentage increases
AP - Fri Mar 07, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
InterMune (ITMN): Stock With Unusual Social Activity
at The Street - Fri Mar 07, 11:03AM CST
Trade-Ideas LLC identified InterMune (ITMN) as an unusual social activity candidate
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
Biotech Stock Roundup: InterMune Grabs Headlines with Impressive Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 05, 9:58AM CST
Last week saw companies like Medivation, Arena and VIVUS reporting fourth quarter results. But, the spotlight remained on InterMune with its late-stage data on Esbriet.
Precious Metals, Health Care Led Mutual Funds In Feb.
at Investor's Business Daily - Tue Mar 04, 5:21PM CST
Mutual fund investors will breathe a sigh of relief when they open their February statements to see that they recouped all of their losses from January plus some. They can rest assured that the U.S. stock market is widely expected to continue...
This Week in Biotech: 2 FDA Approvals and 3 Clinically Impressive Studies
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 01, 2:15PM CST
With the SPDR S&P Biotech Index up 75% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Mar 01, 6:31AM CST
Sure, it's still cold across most of the country. After all, the famous groundhog in Punxsutawney, Pa., did see his shadow in early February. According to the legend, that means we still have a few more weeks of winter. However, some health-care...
InterMune Stuns Markets, but Is It Overvalued?
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 28, 5:03PM CST
InterMune told investors during its fourth quarter conference call that results from its phase 3 Ascend trial studying Esbriet in idiopathic pulmonary fibrosis, or IPF, would likely be released early in the second quarter. Investors ended up...
3 Biotech Companies That Could Be the Next Intercept or InterMune
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 28, 2:43PM CST
Nearly every industry has witnessed a huge rebound since the market bottomed out in March 2009, but few have delivered as strong a gain since 2012 as the biotech sector. Simply put, biotech stocks are on fire. Venture capital is pouring into the...